PHVS (PHVS) Stock Price & Analysis
PHVS (PHVS) rose 2.74% to USD 34.17 as of July 25, 2026 at 07:18 UTC, according to Nexqual real-time market data.
PHVS last closed at USD 33.26; the session ranged USD 33.34–34.38 on volume of 247,620 shares. Market capitalization is $2.39B, with a 52-week range of USD 19.12–36.6 (NMS). Source: Nexqual, July 25, 2026 at 07:18 UTC.
Key Statistics (as of July 25, 2026 at 07:18 UTC)
| Price | USD 34.17 |
|---|---|
| Change | ▲ 2.74% (up) |
| Previous Close | USD 33.26 |
| Open | USD 33.59 |
| Day Range | USD 33.34 – 34.38 |
| 52-Week Range | USD 19.12 – 36.6 |
| Volume | 247,620 shares |
| Market Cap | $2.39B |
| Exchange | NMS |
Technical Analysis (PHVS)
Nexqual's technical model rates PHVS "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 07:18 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.77 (neutral) |
| vs SMA50 | Above (USD 32.41) |
| MACD | 0.43 (positive) |
Analyst Ratings (PHVS)
Wall Street analysts rate PHVS "Strong Buy" based on 14 analysts, with a mean price target of USD 47.02 (range USD 32.06–73.72), per Nexqual as of July 25, 2026 at 07:18 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 47.02 |
| High Target | USD 73.72 |
| Low Target | USD 32.06 |
| Buy / Hold / Sell | 13 / 1 / 0 |
Earnings (PHVS)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.65 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.71 vs est -0.62 ▼ miss |
| 2025-09-30 | USD -0.6 vs est -0.67 ▲ beat |
| 2025-06-30 | USD -0.83 vs est -0.77 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:18 UTC.
Financials & Fundamentals (PHVS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -73.02% |
| Debt / Equity | 0.31 |
| Current Ratio | 11.24 |
| Total Cash | $246.96M |
| Total Debt | $738,891 |
| Free Cash Flow | $-87.68M |
Source: Nexqual, July 25, 2026 at 07:18 UTC.
Financial Health Score (PHVS)
Nexqual rates PHVS's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:18 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $247M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$147M |
| Efficiency | Critical — ROE -73%, ROA -42.3% |
Ownership (PHVS)
| Insider Ownership | +6.13% |
|---|---|
| Institutional Ownership | +85.36% |
| Shares Outstanding | 69.88M |
| Float | 39.67M |
| Short % of Float | +1.98% |
Source: Nexqual, July 25, 2026 at 07:18 UTC.
Leadership (PHVS)
PHVS is led by Berndt Axel Edvard Modig (age 66), Co-Founder, CEO & Executive Director, per Nexqual as of July 25, 2026 at 07:18 UTC.
| Co-Founder, CEO & Executive Director | Berndt Axel Edvard Modig (age 66) |
|---|---|
| President | Peng Lu (age 47) |
| CFO, Chief Legal Officer & Corporate Secretary | David W. Nassif (age 71) |
| Chief Technology Operations Officer | Stefan Abele (age 55) |
| Director of Corporate Relations | Maryann Cimino |
Major Backers & Investors (PHVS)
Notable institutional backers of PHVS include General Atlantic, L.P., FMR, LLC, Foresite Capital Management IV, LLC, according to Nexqual as of July 25, 2026 at 07:18 UTC.
Active Investors
| Investor | Stake |
|---|---|
| General Atlantic, L.P. | 12.28% |
| FMR, LLC | 9.61% |
| Foresite Capital Management IV, LLC | 7.31% |
| venBio Partners LLC | 7.09% |
| Fidelity | 6.93% |
| Viking Global | 5.59% |
| Eqt Fund Management S.a R.l. | 5.24% |
| Deerfield Management Company, L.P | 4.78% |
Source: Nexqual, July 25, 2026 at 07:18 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
| IMCR | Immunocore Holdings plc | USD 35 | ▼ 1.52% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 12.1 | ▲ 12.56% |
| TYRA | Tyra Biosciences, Inc. | USD 30.63 | ▲ 0.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:18 UTC. This page is informational and not investment advice.